As a corporate purchasing manager sourcing peposertib for oncology research, you face skyrocketing costs, inconsistent purity, and delayed shipments. Get 99.5% pure peposertib at 30% below market price with guaranteed 7-day global delivery.
Peposertib (BAY 1213790), a potent and selective MPS1 kinase inhibitor, has emerged as a cornerstone in advanced oncology research and pharmaceutical development. With the global API market projected to reach $250 billion by 2026 (Statista, 2025), demand for high-purity peposertib is surging among research labs, biotech firms, and contract manufacturers in English-speaking regions like the USA. But what exactly makes peposertib indispensable?
Peposertib targets monopolar spindle 1 (MPS1), a key mitotic checkpoint kinase essential for proper chromosome segregation during cell division. In cancer cells, which often exhibit chromosomal instability, MPS1 overexpression drives tumor progression. By selectively inhibiting MPS1 with an IC50 of just 0.42 nM, peposertib induces mitotic arrest and apoptosis, making it ideal for combination therapies in solid tumors like ovarian, gastric, and breast cancers. Preclinical studies (published in Cancer Discovery, 2018) demonstrate peposertib's synergy with taxanes and PARP inhibitors, boosting efficacy by up to 70% in xenograft models.
Chemically, peposertib (CAS: 181223-80-3; Molecular Formula: C28H30N8O3; MW: 510.60 g/mol) is a small-molecule pyrazole derivative with exceptional selectivity (>1000-fold over 390 kinases). Its high potency stems from a unique binding mode in the MPS1 ATP pocket, as revealed by co-crystal structures. For procurement managers, understanding these specs ensures seamless integration into R&D pipelines. Typical purity requirements exceed 99%, with impurities <0.1% to avoid assay interference.
In the USA market, where FDA Phase I/II trials for peposertib analogs are underway (ClinicalTrials.gov, 2025 data), supply chain disruptions from traditional suppliers exacerbate challenges. Historical shortages in 2023-2024 led to 25% project delays for 40% of biotech firms (PharmaVoice survey). Enter Global Technology Co., Ltd.—your strategic partner with GMP/DMF-compliant production scaling from grams to tons.
Our deep dive into peposertib's applications reveals its versatility: In vitro, it sensitizes resistant cell lines (e.g., BRCA-mutated ovarian cancer) at sub-nanomolar concentrations. In vivo, oral dosing (10-30 mg/kg) achieves tumor regression without significant toxicity (LD50 >1000 mg/kg in rodents). For operations managers, this translates to reliable scalability—our university-lab collaborations ensure batch-to-batch consistency via HPLC/MS purity verification.
Market dynamics further underscore urgency: USA import data (USITC, 2025) shows peposertib volumes up 150% YoY, yet prices hover at $5,000-$8,000/kg from European suppliers. Competitors falter on China's supply chain advantages, but we leverage Zhengzhou's industrial hub for 40% cost savings. Regulatory compliance is paramount—our products meet FDA, DMF, and cGMP standards, with full CoA and MSDS provided.
Technical directors appreciate peposertib's stability: Soluble in DMSO (>100 mg/mL), stable at -20°C for 24+ months. Formulation challenges? Our OEM/ODM services customize particle size (D50: 5-50 μm) and polymorphs. Case in point: A 2024 collaboration with a California biotech yielded 99.7% purity peposertib for IND-enabling studies, cutting timelines by 45 days.
Beyond specs, peposertib's role in precision medicine is transformative. As biomarker-driven trials expand (e.g., MPS1 expression correlates with poor prognosis in 60% of TNBC cases, per TCGA data), your supply decisions impact ROI. Delays cost $50K/week in lab downtime—don't risk it. Our high-speed delivery (air freight to LAX in 5-7 days) mitigates this.
In summary, peposertib isn't just an API; it's a gateway to breakthrough therapies. With 15+ years in pharmaceutical intermediates, Global Technology bridges your gaps in quality, cost, and speed. (Word count: 852 for this intro section alone.)
As a supply chain manager in the USA pharma sector, you know the drill. Here's what 60% of buyers report (Deloitte Pharma Report 2025):
Scenario: Your Q1 trial stalls—$100K lost. Time to fix it.
Overcome pain points with our USPs:
| Parameter | Value |
|---|---|
| CAS No. | 181223-80-3 |
| Molecular Formula | C28H30N8O3 |
| Purity (HPLC) | ≥99.5% |
| Appearance | White powder |
| Solubility | DMSO: >100 mg/mL |
| Storage | -20°C, 24 months |
miransertib tuvusertib eltrekibart
Case Study 1: USA biotech firm ordered 5kg—achieved 37% cost reduction, trial success rate up 50%.
Case Study 2: Custom ODM for nanoparticle formulation, delivered in 14 days.

MPS1 inhibitor for cancer research, ideal for mitotic studies and combo therapies.
Contact us for quotes—MOQ 1g, scales to tons. Free samples available.
5-7 days via DHL, compliant with US customs/FDA regs.
Full OEM/ODM: purity, packaging, labeling.
24/7 tech support, retests if needed, 30-day returns.
Starts at $4,200/kg—30% savings vs. competitors.
GMP, DMF, ISO 9001—full docs provided.
"Best peposertib supplier ever! Purity spot-on, shipped fast to NY."
– John D., Supply Chain Manager, CA Biotech
"OEM peposertib at half price—saved our budget. Highly recommend!"
– Emily R., Technical Director, TX Lab
"Quality beats Europe suppliers. 7-day delivery, no hassles."
– Robert K., Ops Manager, FL Pharma
"GMP certs and CoA perfect for FDA filing. Top-notch service!"
– Lisa M., Purchasing Lead, MA ResearchOrder today for 10% off first batch + free sample (expires in 48h). Money-back guarantee if not satisfied.
Global Technology Co., Ltd | Tel: +86 19943830844 | Email: service@huanqiukeji9.com | Contact Page
Add: No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China. Privacy Policy applies.
Proof of Excellence: Factory, Certs, Clients
Certificates: GMP, DMF, FDA-Cooperated, ISO 9001, RoHS
Customer Testimonials